<DOC>
	<DOCNO>NCT00728533</DOCNO>
	<brief_summary>An Open-Label , Multi-Centre , Randomised Parallel-Group Study , Investigating Efficacy Safety Different Degarelix Three-Month Dosing Regimens Patients Prostate Cancer Requiring Androgen Ablation Therapy .</brief_summary>
	<brief_title>Open-Label , Randomised Parallel-Group Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patients , age 18 year old , histologically proven prostate cancer stag endocrine treatment indicate . Screening testosterone level lower limit normal range , globally define &gt; 2.2 ng/mL . Screening PSA level =2 ng/mL . ECOG score =2 . Life expectancy least one year . CRITERIA FOR EVALUATION : Primary endpoint : Probability testosterone castrate level ( =0.5 ng/mL ) Day 28 Day 364 . Secondary endpoint : Probability testosterone castrate level ( =0.5 ng/mL ) Day 56 Day 364 . Serum level testosterone , LH , FSH , PSA time . Time PSA failure define two consecutive increase 50 % , least 5 ng/mL , compare nadir . Plasma level degarelix time . Frequency severity adverse event . Clinically significant change laboratory safety parameter . Clinically significant change physical examination , ECGs , vital sign , body weight .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Prostate Cancer require Androgen Ablation Therapy</keyword>
</DOC>